{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:11:46Z","timestamp":1782951106268,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.ygyno.2008.04.018","type":"journal-article","created":{"date-parts":[[2008,6,14]],"date-time":"2008-06-14T08:44:11Z","timestamp":1213433051000},"page":"140-145","source":"Crossref","is-referenced-by-count":71,"title":["A phase II study of cetuximab\/paclitaxel\/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer"],"prefix":"10.1016","volume":"110","author":[{"given":"Jason","family":"Konner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia A.","family":"DeRosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Gerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martee L.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spriggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.04.018_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2008.04.018_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2008.04.018_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.04.018_bib4","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib5","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/jco.2006.24.18_suppl.5002","volume":"24","author":"Bookman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0092-8674(91)90638-F","article-title":"Growth factors in development, transformation, and tumorigenesis","volume":"64","author":"Cross","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2008.04.018_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/13543784.7.4.553","article-title":"Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials","volume":"7","author":"Strawn","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ygyno.2008.04.018_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.1996.53","article-title":"The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer","volume":"73","author":"Bartlett","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2008.04.018_bib10","first-page":"613","article-title":"EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients","volume":"17","author":"Fischer-Colbrie","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2008.04.018_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00004347-199701000-00010","article-title":"Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors","volume":"16","author":"Niikura","year":"1997","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib12","unstructured":"Tarceva\u00ae (erlotinib) Package Insert. OSI Pharmaceuticals, Inc., Melville, NY 11747, and Genentech, Inc., South San Francisco, CA 94080. March 2007."},{"key":"10.1016\/j.ygyno.2008.04.018_bib13","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.04.018_bib14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"204","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2008.04.018_bib15","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activity mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2008.04.018_bib16","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2008.04.018_bib17","unstructured":"ERBITUX\u00ae (Cetuximab) Package Insert. ImClone Systems Incorporated, New York, NY 10014 and Bristol-Myers Squibb Company, Princeton, NJ 08543: November 2007."},{"key":"10.1016\/j.ygyno.2008.04.018_bib18","first-page":"4322","article-title":"Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies","volume":"53","author":"Fan","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2008.04.018_bib19","first-page":"2957","article-title":"Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice","volume":"4","author":"Prewett","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.04.018_bib20","first-page":"1523","volume":"15","author":"Petit","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ijc.22370","article-title":"Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma","volume":"120","author":"Kawaguchi","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2008.04.018_bib22","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","article-title":"Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines","volume":"13","author":"Kurai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.04.018_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1006302101468","article-title":"Role of an anti-epidermal growth factor receptor in treating cancer","volume":"18","author":"Waksal","year":"1999","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ygyno.2008.04.018_bib24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/85.16.1327","article-title":"Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies","volume":"85","author":"Baselga","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.04.018_bib25","first-page":"4637","article-title":"Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts","volume":"53","author":"Fan","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2008.04.018_bib26","article-title":"Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients (pts) with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens","volume":"19","author":"Rubin","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib27","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1200\/jco.2007.25.18_suppl.5577","article-title":"Phase II trial of single-agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash","volume":"25","author":"Schilder","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib29","doi-asserted-by":"crossref","first-page":"5054a","DOI":"10.1200\/jco.2004.22.14_suppl.5054","article-title":"A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy","volume":"22","author":"Campos","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1525-1438.2005.00137.x","article-title":"Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study","volume":"15","author":"Gordon","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2008.04.018_bib31","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2005.05.4221","article-title":"Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status","volume":"24","author":"Gordon","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2007.11.029","article-title":"Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study","volume":"108","author":"Secord","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib33","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1200\/JCO.2005.03.1997","article-title":"Multicenter phase I\/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer","volume":"23","author":"Thienelt","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib34","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"du Bois","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/dji242","article-title":"Cetuximab therapy and symptomatic hypomagnesemia","volume":"97","author":"Schrag","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.04.018_bib36","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","article-title":"Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab","volume":"25","author":"Khambata-Ford","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.018_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/sj.bjc.6600811","article-title":"Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells","volume":"88","author":"Akagi","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2008.04.018_bib39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1054\/bjoc.2001.1936","article-title":"Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors","volume":"85","author":"Shaheen","year":"2001","journal-title":"Br J Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580800293X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580800293X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T09:56:54Z","timestamp":1588759014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580800293X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S009082580800293X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.04.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}